Stroke is a leading cause of mortality and disability in Mexico and worldwide. Although
current treatment strategies focus on removing oclussion, they do not interrupt the signaling
cascade of neuronal damage. Thus, the search for a cerebroprotective agent that can protect
the entire brain. Melatonin has been proposed as a potential cerebroprotective agent due to
its antioxidant, anti-inflammatory, antiapoptotic, and immunomodulatory effects, which oppose
the pathophysiological mechanisms of cerebrovascular disease. Melatonin has the potential to
improve stroke outcomes and reduce the risk of disability and mortality, making it a
promising therapeutic option for stroke patients.
To assess the efficacy of melatonin in patients with acute ischemic CVD, improve clinical
outcome, and infarct volume.
Phase:
Phase 3
Details
Lead Sponsor:
Coordinación de Investigación en Salud, Mexico
Collaborators:
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado Instituto Mexicano del Seguro Social Universidad Michoacana de San Nicolás de Hidalgo